Sorry, you need to enable JavaScript to visit this website.
Skip to main content

Location Settings

Asia-Pacific

AU -  Sydney
AU -  Melbourne
AU -  Brisbane
CN -  Hong Kong
CN -  Shanghai
IN -  Bangalore
MY -  Kuala Lumpur
PH -  Metro Manila
KR -  Seoul
CN -  Taipei City
TH -  Bangkok
NZ -  New Zealand

North America

US -  San Francisco
US -  Boston

GLOBAL

English

SOLUTIONS

RESOURCES

ABOUT US

Location Settings

Asia-Pacific

AU -  Sydney
AU -  Melbourne
AU -  Brisbane
CN -  Hong Kong
CN -  Shanghai
IN -  Bangalore
MY -  Kuala Lumpur
PH -  Metro Manila
KR -  Seoul
CN -  Taipei City
TH -  Bangkok
NZ -  New Zealand

North America

US -  San Francisco
US -  Boston

GLOBAL

English

Novotech Webinar: Why Asia-Pacific Attracts 60% of All Ongoing and Planned Hepatology Trials Globally

Novotech Webinar: Why Asia-Pacific Attracts 60% of All Ongoing and Planned Hepatology Trials Globally

June 15,2020

The leading Asia-Pacific biotech specialist CRO Novotech is again collaborating with the prestigious biotech and pharma news platform Endpoints News. This webinar focusses on the reasons why the Asia-Pacific is attracting 60% of ongoing and planned hepatology trials globally (source GlobalData).

The webinar will be led by Endpoints News Publisher Arsalan Arif. Participants will include leading KOLs from the Asia-Pacific region and Novotech client Arrowhead Pharmaceuticals:

  • Professor Man-Fung Yuen. Chief of the Division of Gastroenterology and Hepatology and the Deputy Chief of Service of the Department of Medicine, Queen Mary Hospital, Hong Kong.
  • Professor Jacob George. Head, Department of Gastroenterology & Hepatology, Westmead Hospital and Sydney West Local Health District
  • Dr. James Hamilton. Vice President Clinical Development at Arrowhead Pharmaceuticals

Webinar title: Asia-Pacific – a Global hub for Hepatology Clinical Trials

Broadcast time: June 29th 2PM EDT

Click here to register

There are more than 1,300 clinical trials in hepatology, either ongoing or planned, in Asia-Pacific. This represents about 60% of all ongoing and planned hepatology trials globally.

Novotech has completed over 70 clinical projects in hepatology, including studies on hepatitis, NASH and liver cancer.

The webinar will also cover:

  • The latest research and trends in hepatology clinical trials globally and in Asia-Pacific
  • The benefit for biotechnology companies to involve sites in Asia-Pacific for hepatology trials
  • Feedback from sponsors and investigators
  • The status of COVID 19 in the region and the factors that have driven the relatively low spread
  • Regulatory guidance and acceptability of remote monitoring and de-centralized clinical trials in Asia-Pacific
  • Risk management strategies

Novotech says the Asia-Pacific region is highly attractive for biotechs running clinical studies, with its streamlined regulatory environment and advanced medical infrastructure.

Each year Novotech manages more than 200 clinical trials and projects in the region, which boasts large and engaged patient populations and world first medical and research teams and facilities.

Novotech also has just signed its 30th Partnership, a program with leading medical institutions throughout the Asia-Pacific giving Novotech clients unique access to some of the top researchers, investigators and key opinion leaders.